The news in black & white. Never grey.HEALTH

Health · Gene Therapy

FDA Investigates Tumor Risk Tied to Novartis Gene Therapy Zolgensma

Novartis has received nine tumor reports; the agency says benefits still outweigh risks for approved uses, Contemporary Pediatrics and EMJ reported.

Corridor on the second level - NÄL hospital 1
Photo: “Corridor on the second level - NÄL hospital 1” by W.carter, CC0, via Wikimedia Commons.

The Food and Drug Administration said Nov. 6 it is investigating a serious malignancy risk with Zolgensma, Novartis’s one-time gene therapy for spinal muscular atrophy in children under 2, Contemporary Pediatrics reported. Novartis has received nine reports of tumors since the drug’s 2019 approval among more than 6,000 patients treated, the outlet and EMJ both reported.

Three of the tumors were linked to a gene called GLI1, Contemporary Pediatrics reported. In two of them, tumor analysis showed the therapy’s viral vector had inserted into the patient’s DNA near or within GLI1. The cause in the third case is still under investigation, and the FDA said causality is confirmed in only two cases.

The agency extended the concern to Itvisma, a related product given to patients 2 and older, because it uses the same vector. No tumors have been reported with Itvisma. The FDA said it is weighing whether regulatory action is needed but considers the benefits of both products to outweigh the potential risks for approved uses.

Novartis told outlets it notified health authorities in a timely way and that the tumor risk appears in Zolgensma’s prescribing information, EMJ reported. Patient groups said Novartis was slow to share details, and the U.S. groups Cure SMA and the Muscular Dystrophy Association contacted the company, according to EMJ.

Sources

  1. Contemporary Pediatrics, Nov. 9, 2026: FDA safety communication of Nov. 6, case counts, GLI1 findings, Itvisma, FDA position <https://www.contemporarypediatrics.com/view/fda-investigates-malignancy-risk-sma-gene-therapy-zolgensma>
  2. EMJ, Nov. 9, 2026: nine reports, 6,000 patients, Novartis response, advocacy groups <https://www.emjreviews.com/?p=610046>
  3. blue News (DPA), Nov. 7, 2026: tumor sites, GLI1 cases, FDA stance, patient count <https://www.bluewin.ch/en/lifestyle/novartis-reports-nine-cases-of-tumors-caused-by-gene-therapy-li.3665192>

This article was drafted with AI writing tools from the sources listed, checked by a review pass, supervised by the paper’s editors and published by Daniel Varrone. Corrections: editor@monochromechronicles.com

More from Health

Recommended Reading

About this story: Compiled by the The Monochrome Chronicles desk from the sources listed above. Our standards · Report an error · Follow on YouTube

← More Health · Front page